FLUENT Corp.

CNSX:FNT.U Stock Report

Market Cap: US$15.9m

FLUENT Past Earnings Performance

Past criteria checks 0/6

FLUENT's earnings have been declining at an average annual rate of -24.2%, while the Pharmaceuticals industry saw earnings growing at 23.4% annually. Revenues have been growing at an average rate of 6.8% per year.

Key information

-24.23%

Earnings growth rate

-0.68%

EPS growth rate

Pharmaceuticals Industry Growth23.06%
Revenue growth rate6.84%
Return on equityn/a
Net Margin-112.11%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article Nov 09

The Market Doesn't Like What It Sees From FLUENT Corp.'s (CSE:FNT.U) Revenues Yet As Shares Tumble 29%

Unfortunately for some shareholders, the FLUENT Corp. ( CSE:FNT.U ) share price has dived 29% in the last thirty days...
Analysis Article Sep 11

FLUENT Corp.'s (CSE:FNT.U) 33% Dip In Price Shows Sentiment Is Matching Revenues

The FLUENT Corp. ( CSE:FNT.U ) share price has softened a substantial 33% over the previous 30 days, handing back much...
Analysis Article Jul 12

FLUENT Corp. (CSE:FNT.U) Stock Rockets 56% As Investors Are Less Pessimistic Than Expected

FLUENT Corp. ( CSE:FNT.U ) shares have had a really impressive month, gaining 56% after a shaky period beforehand. Not...
Analysis Article May 28

It's A Story Of Risk Vs Reward With FLUENT Corp. (CSE:FNT.U)

There wouldn't be many who think FLUENT Corp.'s ( CSE:FNT.U ) price-to-sales (or "P/S") ratio of 0.3x is worth a...
Analysis Article Dec 27

Slammed 29% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch

To the annoyance of some shareholders, Cansortium Inc. ( CSE:TIUM.U ) shares are down a considerable 29% in the last...
Analysis Article Nov 07

Cansortium Inc. (CSE:TIUM.U) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Cansortium Inc. ( CSE:TIUM.U ) shares have had a horrible month, losing 38% after a relatively good period beforehand...
Analysis Article Oct 25

Cansortium (CSE:TIUM.U) Seems To Be Using A Lot Of Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Sep 04

Cansortium Inc. (CSE:TIUM.U) Soars 30% But It's A Story Of Risk Vs Reward

Cansortium Inc. ( CSE:TIUM.U ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...
Analysis Article Aug 21

Cansortium Inc.'s (CSE:TIUM.U) CEO Compensation Is Looking A Bit Stretched At The Moment

Key Insights Cansortium will host its Annual General Meeting on 27th of August Salary of US$441.7k is part of CEO...
Analysis Article Jul 11

Slammed 32% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Cansortium Inc. ( CSE:TIUM.U ) share price has dived 32% in the last thirty...
Analysis Article Jan 15

Cansortium Inc.'s (CSE:TIUM.U) Shares Not Telling The Full Story

When close to half the companies operating in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...
Analysis Article Nov 30

Is Cansortium (CSE:TIUM.U) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Sep 01

Is Cansortium (CSE:TIUM.U) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Jul 28

Cansortium Inc. (CSE:TIUM.U) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

Cansortium Inc. ( CSE:TIUM.U ) shareholders won't be pleased to see that the share price has had a very rough month...
Analysis Article Mar 08

An Intrinsic Calculation For Cansortium Inc. (CSE:TIUM.U) Suggests It's 26% Undervalued

Key Insights The projected fair value for Cansortium is US$0.13 based on 2 Stage Free Cash Flow to Equity Cansortium's...
Analysis Article Jan 09

Does Cansortium (CSE:TIUM.U) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Sep 09

Here's Why Cansortium (CSE:TIUM.U) Has A Meaningful Debt Burden

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Revenue & Expenses Breakdown

How FLUENT makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:FNT.U Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2682-92370
31 Dec 2587-86390
30 Sep 2584-59360
30 Jun 2585-57360
31 Mar 2585-46350
31 Dec 2487-41340
30 Sep 24104-20380
30 Jun 24103-13360
31 Mar 24100-20340
31 Dec 2397-23310
30 Sep 2395-36290
30 Jun 2392-36280
31 Mar 2390-34260
31 Dec 2288-37260
30 Sep 2283-15270
30 Jun 2276-2270
31 Mar 2270-24270
31 Dec 2165-19300
30 Sep 2162-31320
30 Jun 2161-47330
31 Mar 2157-28350
31 Dec 2052-37320
30 Sep 2047-48350
30 Jun 2040-51350
31 Mar 2033-51350
31 Dec 1929-53410
30 Sep 1924-54410
30 Jun 1919-13390
31 Mar 1914-9330
31 Dec 1880210
30 Sep 18316140
30 Jun 180-1590
31 Mar 180-1680
31 Dec 170-1080

Quality Earnings: FNT.U is currently unprofitable.

Growing Profit Margin: FNT.U is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: FNT.U is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.

Accelerating Growth: Unable to compare FNT.U's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FNT.U is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (64.6%).


Return on Equity

High ROE: FNT.U's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/13 20:39
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

FLUENT Corp. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell StanleyBeacon Securities Limited
Jonathan DeCourceyBTIG
Robert BurlesonCanaccord Genuity